In a small lab in Bellinzona, Switzerland, a vial of blood drawn from a West Nile virus survivor in Serbia may hold the key to protecting millions from a growing global threat. As mosquito-borne viruses creep into new regions, including temperate parts of Europe, the need for effective treatments has never been more urgent. West Nile virus (WNV), which can lead to severe brain inflammation and death, currently has no approved antiviral therapy or human vaccine. But now, a breakthrough study led by Davide Robbiani’s team at the Institute for Research in Biomedicine (IRB), affiliated with Università della Svizzera italiana, has identified two powerful human monoclonal antibodies that neutralize not only WNV but also a suite of related, often deadly, encephalitic viruses.
The research, published in Immunity in 2026, analyzed immune responses in people who had recovered from West Nile infection in Serbia—a country where outbreaks have become increasingly common. From that analysis, scientists isolated antibody W010, which binds to a precise site on the virus’s envelope domain III, a critical protein the virus uses to invade human cells. When tested in mice, W010 offered complete protection even when administered five days after exposure—an extraordinary window for a therapeutic, suggesting it could be effective in real-world clinical settings where treatment often starts after symptoms appear.
Even more promising is antibody W014, which demonstrated broad cross-neutralizing power. It effectively blocked not just West Nile, but also Japanese encephalitis, Murray Valley encephalitis, St. Louis encephalitis, and Usutu viruses—pathogens responsible for outbreaks across Asia, Australia, North America, and increasingly, Europe. This rare breadth suggests W014 could become the foundation for a universal countermeasure against a whole family of flaviviruses, which collectively threaten hundreds of millions of people worldwide.
The implications extend beyond treatment. By mapping exactly where these antibodies bind to the virus, the team has revealed vulnerable sites on WNV that could guide the design of future vaccines. Currently, prevention relies solely on mosquito control and personal protection—strategies that are often insufficient during surges in transmission. With climate change expanding the range of mosquito vectors, the number of West Nile cases in Europe has risen sharply in recent years, making the development of medical interventions a public health priority.
While further clinical testing lies ahead, the discovery of W010 and W014 marks a turning point. These naturally derived human antibodies—born from the resilience of survivors—offer a dual path forward: one toward life-saving therapies, and another toward smarter, more targeted vaccines. As research moves into the next phase, the hope is that what began with a few blood samples from Serbia could one day shield communities across continents from some of the world’s most insidious brain-infecting viruses.